GlassScriptPhysician profile
Alexus M Black
NPI 1538741343
$4,868.52
in general payments reported to CMS, 2019-2025
54 companies · $1,581 in 2025
The $1,581 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $994 · 2023: $864 · 2024: $1,429 · 2025: $1,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,782 · Education: $92.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,781.57 |
| Education | $92.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $638.80 | 2022-2025 | Piqray, Kisqali |
| E.R. Squibb & Sons, L.L.C. | $309.65 | 2022-2025 | Reblozyl, Opdivo |
| Abbvie INC. | $255.05 | 2024-2025 | |
| Glaxosmithkline, LLC. | $241.41 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Daiichi Sankyo INC. | $228.60 | 2022-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $226.97 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $218.32 | 2022-2025 | Rybrevant, Erleada, Darzalex |
| Astrazeneca Pharmaceuticals LP | $210.25 | 2022-2025 | Enhertu, Imfinzi, Calquence |
| Incyte Corporation | $195.47 | 2022-2025 | Jakafi, Monjuvi |
| Eisai INC. | $187.18 | 2022-2024 | |
| Gilead Sciences, INC. | $146.56 | 2022-2025 | Trodelvy |
| Lilly USA, LLC | $146.54 | 2022-2025 | Jaypirca, Verzenio |
| Pfizer INC. | $130.71 | 2022-2025 | |
| Astellas Pharma Global Development | $125.44 | 2023 | Padcev |
| Kite Pharma, INC. | $125.40 | 2022-2025 | Yescarta |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $125.00 | 2024 | Epkinly |
| Seagen INC. | $99.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $71.01 | 2025 | Libtayo |
| Astellas Pharma US INC | $66.68 | 2023-2025 | Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $65.98 | 2023-2024 | Alunbrig, Fruzaqla |
| Puma Biotechnology, INC. | $65.83 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $63.00 | 2023-2025 | Monoferric, Cosela |
| Alexion Pharmaceuticals, INC. | $57.79 | 2023-2025 | Ultomiris |
| Array Biopharma INC | $57.06 | 2022-2025 | Lorbrena, Braftovi, Xalkori |
| Taiho Oncology, INC. | $56.57 | 2024-2025 | |
| Amgen INC. | $54.31 | 2022-2023 | Xgeva, Vectibix, Nplate |
| Pharmaessentia USA Corporation | $47.19 | 2024-2025 | Besremi |
| Medtronic, INC. | $47.11 | 2023 | Cobalt Dr Mri Surescan, Micra, Advisa Dr Mri Surescan |
| Emd Serono, INC. | $43.25 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $41.09 | 2023-2025 | Fotivda |
| Ipsen Biopharmaceuticals, INC | $39.34 | 2022-2023 | Onivyde, Somatuline Depot |
| Genentech USA, INC. | $34.96 | 2022 | |
| Legend Biotech USA INC. | $28.95 | 2025 | Carvykti |
| Novocure INC. | $28.31 | 2024 | Optune |
| Geron Corporation | $26.83 | 2025 | Rytelo |
| Dendreon Pharmaceuticals LLC | $26.09 | 2025 | Provenge |
| G1 Therapeutics, INC. | $24.92 | 2022 | |
| Immunogen, INC. | $24.47 | 2023 | Elahere |
| Delcath Systems | $23.58 | 2025 | Hepzato Kit |
| Pharmacyclics LLC, An Abbvie Company | $23.35 | 2023 | Imbruvica |
| Stemline Therapeutics INC. | $22.72 | 2025 | Orserdu |
| Myriad Genetic Laboratories, INC. | $20.95 | 2023 | Myrisk |
| Azurity Pharmaceuticals, INC. | $20.56 | 2025 | Danziten |
| Epizyme, INC. | $19.50 | 2022 | |
| Global Blood Therapeutics, INC. | $19.31 | 2022 | |
| Sobi, INC | $18.25 | 2023 | |
| Morphosys, US INC. | $17.51 | 2022 | |
| Sun Pharmaceutical Industries INC. | $17.05 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.71 | 2025 | |
| Janssen Pharmaceuticals, INC | $16.70 | 2023 | Xarelto |
| Blueprint Medicines Corporation | $16.00 | 2023 | Ayvakit |
| Celgene Corporation | $15.38 | 2022 | |
| Acrotech Biopharma INC. | $14.44 | 2022 | |
| Rigel Pharmaceuticals, INC. | $5.42 | 2023 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexus Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.